Comparison of non-invasive approaches to red marrow dosimetry for radiolabelled monoclonal antibodies
Identifieur interne : 000205 ( Main/Exploration ); précédent : 000204; suivant : 000206Comparison of non-invasive approaches to red marrow dosimetry for radiolabelled monoclonal antibodies
Auteurs : RBID : ISTEX:259_1994_Article_BF00188669.pdfEnglish descriptors
- KwdEn :
Abstract
Red marrow is usually the dose-limiting organ during radioimmunotherapy. Several non-invasive approaches to calculate the red marrow dose have been proposed. We compared four approaches to analyse the differences in calculated red marrow doses. The data were obtained from immunoscintigraphy of two antibodies with different red marrow kinetics [iodine-131-16.88 IgM and indium- 111-OV-TL-3 F(ab′)2]. The approaches are based on, respectively, homogeneously distributed activity in the body, a red marrow-blood activity concentration ratio of 0.3, scintigraphic quantification, and a combination of the second and third approaches. This fourth approach may be more adequate because of its independence from the chosen antibody. In addition, the influence of activity accumulation in liver, kidneys or cancellous bone on red marrow dose was studied. The calculated red marrow dose varied between 0.14 and 0.42 mGy/MBq for 111 In-OV TL-3 and between 0.13 and 0.68 mGy/MBq for 131I-16-88. If the radiopharmaceutical shows high affinity for cancellous bone or another organ situated near the red marrow, the activity in these organs must be included in dose calculations. This study shows a large variation in calculated red marrow dose and selection of the definitive non-invasive approach awaits validation.
DOI: 10.1007/BF00188669
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title>Comparison of non-invasive approaches to red marrow dosimetry for radiolabelled monoclonal antibodies</title><author><name>Marian A. B. D. Plaizier</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Nuclear Medicine, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV</wicri:regionArea><wicri:noRegion>HV</wicri:noRegion></affiliation></author><author><name>Jan C. Roos</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Nuclear Medicine, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV</wicri:regionArea><wicri:noRegion>HV</wicri:noRegion></affiliation></author><author><name>Gerrit J. J. Teule</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Nuclear Medicine, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV</wicri:regionArea><wicri:noRegion>HV</wicri:noRegion></affiliation></author><author><name>Erik B. van Dieren</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Nuclear Medicine, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV</wicri:regionArea><wicri:noRegion>HV</wicri:noRegion></affiliation></author><author><name>Wim den Hollander</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Nuclear Medicine, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV</wicri:regionArea><wicri:noRegion>HV</wicri:noRegion></affiliation></author><author><name>Hidde J. Haisma</name><affiliation wicri:level="1"><mods:affiliation>Department of Medical Oncology, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV</wicri:regionArea><wicri:noRegion>HV</wicri:noRegion></affiliation></author><author><name>Robert L. DeJager</name><affiliation wicri:level="1"><mods:affiliation>Organon Teknika Corp., Biotechnology Research Institute, 1330-A Picard Drive, 20850-4373, Rockville, MD, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Organon Teknika Corp., Biotechnology Research Institute, 1330-A Picard Drive, 20850-4373, Rockville, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name>Arthur van Lingen</name><affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Nuclear Medicine, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV</wicri:regionArea><wicri:noRegion>HV</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="RBID">ISTEX:259_1994_Article_BF00188669.pdf</idno><date when="1994">1994</date><idno type="doi">10.1007/BF00188669</idno><idno type="wicri:Area/Main/Corpus">000A55</idno><idno type="wicri:Area/Main/Curation">000A55</idno><idno type="wicri:Area/Main/Exploration">000205</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dosimetry</term><term>Monoclonal antibodies</term><term>Red marrow</term><term>Scintigraphy</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">Red marrow is usually the dose-limiting organ during radioimmunotherapy. Several non-invasive approaches to calculate the red marrow dose have been proposed. We compared four approaches to analyse the differences in calculated red marrow doses. The data were obtained from immunoscintigraphy of two antibodies with different red marrow kinetics [iodine-131-16.88 IgM and indium- 111-OV-TL-3 F(ab′)2]. The approaches are based on, respectively, homogeneously distributed activity in the body, a red marrow-blood activity concentration ratio of 0.3, scintigraphic quantification, and a combination of the second and third approaches. This fourth approach may be more adequate because of its independence from the chosen antibody. In addition, the influence of activity accumulation in liver, kidneys or cancellous bone on red marrow dose was studied. The calculated red marrow dose varied between 0.14 and 0.42 mGy/MBq for 111 In-OV TL-3 and between 0.13 and 0.68 mGy/MBq for 131I-16-88. If the radiopharmaceutical shows high affinity for cancellous bone or another organ situated near the red marrow, the activity in these organs must be included in dose calculations. This study shows a large variation in calculated red marrow dose and selection of the definitive non-invasive approach awaits validation.</div></front></TEI><mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="b985334a15c6044c8278441c5d70963eba978b00"><titleInfo lang="eng"><title>Comparison of non-invasive approaches to red marrow dosimetry for radiolabelled monoclonal antibodies</title></titleInfo><name type="personal"><namePart type="given">Marian A. B. D.</namePart><namePart type="family">Plaizier</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV, The Netherlands</affiliation></name><name type="personal"><namePart type="given">Jan C.</namePart><namePart type="family">Roos</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV, The Netherlands</affiliation></name><name type="personal"><namePart type="given">Gerrit J. J.</namePart><namePart type="family">Teule</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV, The Netherlands</affiliation></name><name type="personal"><namePart type="given">Erik B.</namePart><namePart type="family">van Dieren</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV, The Netherlands</affiliation></name><name type="personal"><namePart type="given">Wim</namePart><namePart type="family">den Hollander</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV, The Netherlands</affiliation></name><name type="personal"><namePart type="given">Hidde J.</namePart><namePart type="family">Haisma</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Medical Oncology, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV, The Netherlands</affiliation></name><name type="personal"><namePart type="given">Robert L.</namePart><namePart type="family">DeJager</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Organon Teknika Corp., Biotechnology Research Institute, 1330-A Picard Drive, 20850-4373, Rockville, MD, USA</affiliation></name><name type="personal"><namePart type="given">Arthur</namePart><namePart type="family">van Lingen</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Department of Nuclear Medicine, Free University Hospital, De Boelelaan 1117, 1081, Amsterdam, HV, The Netherlands</affiliation></name><typeOfResource>text</typeOfResource><genre>Original Articles</genre><genre>Original Paper</genre><originInfo><publisher>Springer-Verlag, Berlin/Heidelberg</publisher><dateCreated encoding="w3cdtf">1993-07-02</dateCreated><dateValid encoding="w3cdtf">2004-07-10</dateValid><copyrightDate encoding="w3cdtf">1994</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="eng">Red marrow is usually the dose-limiting organ during radioimmunotherapy. Several non-invasive approaches to calculate the red marrow dose have been proposed. We compared four approaches to analyse the differences in calculated red marrow doses. The data were obtained from immunoscintigraphy of two antibodies with different red marrow kinetics [iodine-131-16.88 IgM and indium- 111-OV-TL-3 F(ab′)2]. The approaches are based on, respectively, homogeneously distributed activity in the body, a red marrow-blood activity concentration ratio of 0.3, scintigraphic quantification, and a combination of the second and third approaches. This fourth approach may be more adequate because of its independence from the chosen antibody. In addition, the influence of activity accumulation in liver, kidneys or cancellous bone on red marrow dose was studied. The calculated red marrow dose varied between 0.14 and 0.42 mGy/MBq for 111 In-OV TL-3 and between 0.13 and 0.68 mGy/MBq for 131I-16-88. If the radiopharmaceutical shows high affinity for cancellous bone or another organ situated near the red marrow, the activity in these organs must be included in dose calculations. This study shows a large variation in calculated red marrow dose and selection of the definitive non-invasive approach awaits validation.</abstract><subject lang="eng"><genre>Key words</genre><topic>Red marrow</topic><topic>Dosimetry</topic><topic>Monoclonal antibodies</topic><topic>Scintigraphy</topic></subject><relatedItem type="series"><titleInfo type="abbreviated"><title>Eur J Nucl Med</title></titleInfo><titleInfo><title>European Journal of Nuclear Medicine</title><partNumber>Year: 1994</partNumber><partNumber>Volume: 21</partNumber><partNumber>Number: 3</partNumber></titleInfo><genre>Archive Journal</genre><originInfo><dateIssued encoding="w3cdtf">1994-03-01</dateIssued><copyrightDate encoding="w3cdtf">1994</copyrightDate></originInfo><subject usage="primary"><topic>Medicine & Public Health</topic><topic>Imaging / Radiology</topic><topic>Nuclear Medicine</topic></subject><identifier type="issn">0340-6997</identifier><identifier type="issn">Electronic: 1619-7089</identifier><identifier type="matrixNumber">259</identifier><identifier type="local">IssueArticleCount: 20</identifier><recordInfo><recordOrigin>Springer-Verlag, 1994</recordOrigin></recordInfo></relatedItem><identifier type="doi">10.1007/BF00188669</identifier><identifier type="matrixNumber">Art7</identifier><identifier type="local">BF00188669</identifier><accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition><accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition><accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition><accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition><accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition><accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition><part><extent unit="pages"><start>216</start><end>222</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1994</recordOrigin><recordIdentifier>259_1994_Article_BF00188669.pdf</recordIdentifier></recordInfo></mods></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000205 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000205 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:259_1994_Article_BF00188669.pdf
|texte= Comparison of non-invasive approaches to red marrow dosimetry for radiolabelled monoclonal antibodies
}}
| This area was generated with Dilib version V0.5.81. |  |